Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Medtronic
Colorcon
Harvard Business School
McKesson

Last Updated: October 2, 2022

Investigational Drug Information for SNX-5422


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug SNX-5422?

SNX-5422 is an investigational drug.

There have been 16 clinical trials for SNX-5422. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2006.

The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Hematologic Neoplasms. The leading clinical trial sponsors are Esanex Inc., Serenex, Inc., and National Cancer Institute (NCI).

Recent Clinical Trials for SNX-5422
TitleSponsorPhase
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLLEsanex Inc.Phase 1
Safety and Activity of SNX-5422 Plus Ibrutinib in CLLEsanex Inc.Phase 1
Study of SNX-5422 in TP53 Null CancersEsanex Inc.Phase 2

See all SNX-5422 clinical trials

Clinical Trial Summary for SNX-5422

Top disease conditions for SNX-5422
Top clinical trial sponsors for SNX-5422

See all SNX-5422 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Medtronic
Colorcon
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.